What is ArrePath?
ArrePath is a cutting-edge biotech company headquartered in Princeton, NJ, dedicated to leveraging advanced artificial intelligence and machine learning platforms. The company's core focus is on discovering and developing novel small-molecule therapeutics, with a particular emphasis on creating new antibiotics to address the critical global challenge of antimicrobial resistance. By applying sophisticated computational approaches, ArrePath aims to accelerate the drug discovery pipeline and bring much-needed treatments to market.
How much funding has ArrePath raised?
ArrePath has raised a total of $20M across 1 funding round:
Angel/Seed
$20M
Angel/Seed (2022): $20M with participation from Innospark Ventures, Boehringer Ingelheim Venture Fund, and Insight Partners
Key Investors in ArrePath
Innospark Ventures
Innospark Ventures is an early-stage venture fund based in Boston that invests in the AI-powered economy, focusing on foundational, deeply impactful ideas and fostering founder-friendly partnerships.
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund invests in pioneering science and first-in-class therapeutics across modalities, driving innovation globally to redefine care standards and develop new medicines.
Insight Partners
Insight Partners is a venture capital firm that supports software portfolio companies through its dedicated platform, GO, aimed at fostering connections, leadership, and growth as companies scale.
What's next for ArrePath?
With the recent infusion of enterprise-level capital, ArrePath is strategically positioned to advance its research and development pipeline. This significant backing suggests a growth phase, likely focused on scaling operations, expanding its R&D capabilities, and potentially moving promising drug candidates through preclinical and clinical trials. The company's commitment to tackling antimicrobial resistance, a pressing public health issue, indicates a strong potential for future impact and continued investment in this vital area of medical science.
See full ArrePath company page
